Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Failure (M23-698, Japan)
jRCT2061230029Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in hidradenitis suppurativa (HS) (9 arms), sponsored by AbbVie Inc. Primary endpoint: HiSCR 50 response at Week 16. Started Sep 2023; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2061230029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230029.